Harmony Biosciences (HRMY) WAKIX Revenue Keeps Time, BP-205 Faces the Sunrise
In HRMY’s Q2 2026 release, HRMY demonstrates a solid revenue glow while laying out a pipeline timetable that could push the stock beyond the wakeful confines of today’s numbers. Look for EPS and EPS consensus in next filings, as investors weigh earnings surprise risk against a revenue forecast that Harmony aims to sustain.
Overview: WAKIX drives a 30% YoY revenue lift
The company reported Q2 2026 net revenue of $261.3 million, marking a 30% year-over-year increase that underscores durable demand for WAKIX®. Harmony notes the franchise clocked an average of roughly 8,950 patients in the quarter, up about 450 from the prior period.
Guidance remains clear: Harmony reiterates a full-year revenue forecast of $1.0 billion to $1.04 billion. For readers who care about EPS or the EPS consensus, the press release does not provide an EPS figure, leaving a natural opening for earnings surprise analysis to hinge on next quarter’s numbers rather than today’s headline revenue number.
In a world where headlines are currency, Harmony’s revenue narrative keeps the lights on. But the street will want to see whether EPS translates with the same reliability as WAKIX’s prescriptive growth in narcolepsy-adjacent markets.
Pipeline update: BP-205 eyeing best-in-class status
The company highlights encouraging Phase 1 single ascending dose (SAD) data for its orexin-2 receptor (OX2R) agonist, BP-205, noting favorable pharmacokinetic (PK) profiles and safety/tolerability. Harmony states these data reinforce its conviction that BP-205 could emerge as a best-in-class orexin-2 agonist. The plan is deliberate: begin Phase 2 trials for BP-205 in mid-2027 to evaluate multiple CNS indications, signaling a shift from a single-drug focus toward a broader CNS portfolio—and a potential uplift to the company’s revenue forecast trajectory if Phase 2 reads well.
On the chemistry of future profits, the company frames BP-205 as a centerpiece in its orexin strategy, while acknowledging Phase 2 timing remains a key risk. In other words, the longer you wait for Phase 2, the more you need investors to trust that the PK/tolerability signals translate into real-world efficacy across indications.
Regulatory milestones: Pitolisant progress and PDUFA timing
Regulatory news trotted into the mix with Pitolisant GR (growth indications) NDA acceptance in July. The expected PDUFA date is April 1, 2027, a date investors will circle as a potential near-term catalyst for the stock. Separately, Harmony reiterates that Pitolisant HD is on track for Phase 3 topline data in 2027, with a target PDUFA date in 2028. The combined regulatory cadence provides a two-pronged timeline: a near-term NDA milestone for one aspect of the portfolio and a longer runway for the high-dose variant to emerge in a later cycle.
Voices from the company: leadership commentary
“Our record second-quarter revenue reflects sustained demand for WAKIX and keeps us firmly on track to deliver over $1 billion in revenue this year. With this strong foundation, we are aggressively advancing our pipeline, with our orexin-2 agonist BP-205 as the centerpiece, that we believe can create significant long-term value for both patients and shareholders,” said Jeffrey M. Dayno, MD, President and Chief Executive Officer of Harmony Biosciences. “The Phase 1 clinical PK and safety/tolerability data for BP-205 that we shared today, together with pre-clinical data demonstrating the highest potency of any orexin-2 agonist currently in the clinic, reinforce our conviction that BP-205 has the potential to be the best-in-class orexin-2 agonist.
What this means for Harmony and sector peers
The quarter’s momentum suggests Harmony’s WAKIX franchise remains a reliable driver of value, even as management tees up a pipeline that could diversify revenue streams beyond a single product. If BP-205 translates SAD/SAD-like PK data into meaningful Phase 2 outcomes, Harmony could pivot from a one-drug growth story to a multi-indication play, raising the bar for peers racing to unlock the orexin-2 axis. Of course, the usual risks apply: regulatory hurdles, trial recruitment pace, and the ever-present possibility that Phase 2 results disappoint. Still, the cadence of NDA approvals and Phase 3 timelines creates a framework where EPS consensus and earnings surprise dynamics will matter less in isolation and more as a function of how well the pipeline compounds earnings visibility over time.
Analysts will be watching not just the headline revenue forecast but the trajectory of operating leverage as WAKIX matures and BP-205 progresses. If the company sustains or improves its margins while financing a growing development engine, Harmony could emerge as a more durable compound in a sector crowded with flashy quarterly swings.
Bottom line
Harmony’s Q2 narrative is less about a one-quarter surprise and more about a strategic plan gaining momentum: continued WAKIX demand, a pipeline aimed at best-in-class status for BP-205, and a regulatory runway with Pitolisant that could unlock additional value in 2027 and beyond. For investors tracking EPS and the EPS consensus, this is a story where the near-term numbers on HRMY stock price sit alongside a longer-term thesis that hinges on pipeline execution as much as revenue growth.